中國的CNBG已向阿聯酋提供了300萬劑COVID-19疫苗

Recently Yahoo News on-line reported the following:

China's CNBG has supplied 3 million COVID-19 vaccine doses to UAE

Reuters Tue., January 5, 2021, 3:10 a.m. PST

BEIJING (Reuters) - United Arab Emirates (UAE) has received a total of three million COVID-19 vaccine doses from China National Biotec Group (CNBG), the company said on Tuesday.

CNBG has moved into late-stage clinical trials two COVID-19 vaccine candidates respectively developed by its units in Beijing and Wuhan city. The Beijing unit's shot obtained a green light last week for general public use in China.

CNBG is a subsidiary of state-backed China National Pharmaceutical Group (Sinopharm).

"According to preliminary feedback from UAE, emergency use shows that Sinopharm CNBG's COVID-19 vaccine is safe in large-scale use and has significantly reduced the disease in vaccinated people," CNBG said in an article published on Chinese social media WeChat, without specifying which candidate it referred to.

The firm didn't break down the numbers of doses for each candidate in its supply to UAE. It's not immediately clear how many of these doses were used in clinical trials and how many in real-life use.

Pakistan said last week it would purchase 1.2 million doses of the vaccine developed by CNBG's Beijing unit.

Translation

北京（路透社）- 中國國家生物技術集團（CNBG）週二表示，阿拉伯聯合酋長國 (UAE）已從它的集团公司獲得了三百萬劑COVID-19疫苗。

中国生物技术集团公司已將其分別在北京和武漢的部門研製的兩種候選COVID-19疫苗進行了後期臨床試驗，北京單位的疫苗注射在上週獲得了中國公開使用的許可。

中国生物技术集团公司是國家支持的中國醫藥集團（Sinopharm）的子公司。

中国生物技术集团公司在中國社交媒體微信上發表的一篇文章中說： “根據阿聯酋的初步反饋，緊急使用顯示國藥CNBG的COVID-19疫苗可以安全地大規模使用，並大大降低了接種疫苗的人的發病。” 它沒有指出是哪個候選疫苗。

該公司沒有細分其向阿聯酋供應的每位候選人的劑量數量，也不清楚立即在臨床試驗中使用多少劑量以及在現實生活中使用多少劑量。

巴基斯坦上週表示，它將購買120萬劑中国生物技术集团北京分公司研發的疫苗。

              So, CNBG's COVID-19 vaccine is now made available to United Arab Emirates. I am interested to know how this vaccine will perform after the vaccination starts.